Given an abstract from a research paper, your task is to identify and label relationships between chemical compounds and genes mentioned in the abstract.

The relationship type must be one of ['DOWNREGULATOR', 'SUBSTRATE', 'INDIRECT-REGULATOR', 'PART-OF', 'MODULATOR-ACTIVATOR', 'REGULATOR', 'INHIBITOR', 'COFACTOR', 'UPREGULATOR', 'ACTIVATOR', 'ANTAGONIST', 'NOT', 'INDIRECT-DOWNREGULATOR', 'SUBSTRATE_PRODUCT-OF', 'INDIRECT-UPREGULATOR', 'AGONIST', 'PRODUCT-OF', 'MODULATOR', 'DIRECT-REGULATOR', 'UNDEFINED', 'AGONIST-INHIBITOR', 'AGONIST-ACTIVATOR', 'MODULATOR-INHIBITOR'].

Please format your output as a JSON array. Each entry in the array should express a single relation, formatted as ["<Entity_A>", "<RELATION_A_B>", "<Entity_B>"]. If no relations can be found, please output an empty JSON array [].

Abstract:

Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. The effects of histamine H1-receptor antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks. Promethazine, 150 mg/d, in 11 patients and homochlorcyclizine, 60 mg/d, in the others were coadministered for at least 1 week. Blood sampling was performed before and during coadministration of promethazine or homochlorcyclizine and 1 week after the discontinuation, together with clinical assessments by Brief Psychiatric Rating Scale (BPRS) and Udvalg for kliniske undersogelser (UKU) side effect rating scale. The Css (mean + /- SD) of haloperidol and reduced haloperidol during promethazine coadministration (27.6 + /- 24.9 and 8.6 + /- 13.2 ng/mL) were significantly higher than those before the coadministration (12.7 + /- 10.8 and 5.0 + /- 6.0 ng/mL; P < 0.01) or 1 week after the discontinuation (15.6 + /- 14.8 and 5.8 + /- 7.9 ng/mL; P < 0.05). The Css of haloperidol and reduced haloperidol during homochlorcyclizine coadministration (14.9 + /- 8.1 and 6.4 + /- 5.4 ng/mL) were also significantly higher than those before the coadministration (10.9 + /- 7.2 and 3.8 + /- 3.6 ng/mL; P < 0.01) or 1 week after the discontinuation (12.9 + /- 7.4 and 4.8 + /- 4.1 ng/mL; P < 0.05). No change in BPRS or UKU score was found throughout the study. Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the CYP2D6-catalyzed metabolism of haloperidol and reduced haloperidol.
[["promethazine", "INHIBITOR", "CYP2D6"], ["promethazine", "ANTAGONIST", "Histamine H1-receptor"], ["homochlorcyclizine", "ANTAGONIST", "histamine H1-receptor"], ["promethazine", "ANTAGONIST", "histamine H1-receptor"], ["homochlorcyclizine", "ANTAGONIST", "Histamine H1-receptor"], ["homochlorcyclizine", "INHIBITOR", "CYP2D6"]]